Morgan Stanley Alterity Therapeutics LTD Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.3 - $4.9 $6,780 - $110,740	-22,600 Reduced 4.13%	524,364 $183,000
Q3 2022 Nov 14, 2022	SELL	$0.01 - $4.8 $483 - $231,840	-48,300 Reduced 8.11%	546,964 $241,000
Q2 2022 Oct 27, 2022	BUY	$0.01 - $0.02 $153 - $306	15,300 Added 2.64%	595,264 $364,000
Q2 2022 Aug 15, 2022	BUY	$0.01 - $0.02 $153 - $306	15,300 Added 2.64%	595,264 $364,000
Q1 2022 Oct 27, 2022	SELL	$0.01 - $0.02 $153 - $306	-15,300 Reduced 2.57%	579,964 $481,000
Q1 2022 May 13, 2022	BUY	$0.01 - $0.02 $201 - $402	20,100 Added 3.59%	579,964 $481,000
Q4 2021 Feb 14, 2022	SELL	$0.01 - $0.02 $91 - $182	-9,100 Reduced 1.6%	559,864 $403,000
Q3 2021 Nov 15, 2021	BUY	$0.02 - $0.03 $11,379 - $17,068	568,964 New	568,964 $723,000

Ticker ATHE
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,114,600
Market Cap $171M
Description
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.